Steven J Shafer, 662052 Ridgeview Dr, Longmont, CO 80504

6732093, May 4, 2004

May 31, 2001

09/873132

Jean-Max Vally - San Francisco CA
Laura S. Diamondstone - San Francisco CA
Jon Hartlaub - Mountain View CA
E. Gregory Lee - Alto CA
Steven Shafer - Mountain View CA

Pharsight Corporation - Mountain View CA

G06F 1730

707 4, 707 3, 707 5

Methods of performing temporal logic queries, and systems for performing temporal logic queries, are disclosed. Data associated with statistical reliability criteria are annotated in a data source. Baseline data stored in the data source is summarized. Temporal data requests made upon the data source are automatically merged with the data associated with the statistical reliability criteria, to produce a statistically valid data query. Data query results are optionally provided to a statistics module for processing of statistical analyses.

7648981, Jan 19, 2010

Mar 1, 2004

10/788466

Steven Louis Shafer - Mountain View CA, US
Orlando Ricardo Hung - Halifax, CA
Diana Helen Pliura - Mississauga, CA

YM Biosciences Inc. - Mississauga

A61K 9/127
A61K 9/12
A61K 31/445
A61K 31/4468
A61M 15/00
A61M 13/00

5142255, 424450, 12820217, 12820315, 12820014

An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing, method of administering, kit containing, and uses of same. The formulation contains at least one rapid-onset opioid and preferably also contains a sustained-effect opioid to reduce the frequency of administration. The invention employs the side effects of the opioid formulation to permit patients to self-limit drug intake, thereby avoiding toxicity while achieving analgesia. A pharmacokinetic and pharmacodynamic model is employed to determine optimum drug formulations and optimum parameters for administration.

7648982, Jan 19, 2010

Aug 27, 2004

10/927145

Steven Louis Shafer - Mountain View CA, US
Orlando Ricardo Hung - Halifax, CA
Diana Helen Pliura - Mississauga, CA

YM Biosciences Inc. - Mississauga

A61K 9/127
A61K 9/12
A61K 31/445
A61K 31/4468
A61M 15/00
A61M 13/00

5142255, 424450, 12820217, 12820315, 12820014

An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing, method of administering, kit containing, and uses of same. The formulation contains at least one rapid-onset opioid and preferably also contains a sustained-effect opioid to reduce the frequency of administration. The invention employs the side effects of the opioid formulation to permit patients to self-limit drug intake, thereby avoiding toxicity while achieving analgesia. A pharmacokinetic and pharmacodynamic model is employed to determine optimum drug formulations and optimum parameters for administration.

2005013, Jun 23, 2005

Dec 18, 2003

10/740716

Steven Shafer - Mountain View CA, US

A61K031/573
A61K031/24
A61K031/137

514171000, 514537000, 514649000

The present invention provides compositions and methods for improved local anesthesia and/or analgesia, in which onset of action is rapid, the risk of toxicity is low, and the effect is sustained. More particularly, the present invention provides a combination of at least two ester anesthetics for administration to a subject, where at least one ester anesthetic provides a rapid onset of action and at least one ester anesthetic provides sustained activity. The compositions of the present invention are useful for the production of analgesia and/or anesthesia and are particularly useful for the prophylaxis and/or treatment of pain.

2006011, May 25, 2006

May 17, 2005

11/131778

Steven Shafer - Mountain View CA, US
Pamela Flood - Closter NJ, US
Thomas Jenkins - La Honda CA, US

A61K 31/485
A61K 31/4439
A61K 31/22
A61K 31/14

514282000, 514340000, 514343000, 514642000, 514546000

Disclosed herein are compositions and methods which treat or prevent pain in a subject. More specifically, disclosed herein are compositions of nicotinic agonists, salts, hydrates, solvates, prodrugs or metabolites thereof and opioid agonists salts, hydrates, solvates, prodrugs or metabolites thereof, pharmaceutical compositions thereof and methods of using these compositions and pharmaceutical compositions thereof to treat or prevent pain in a subject. Also disclosed are methods of treating or preventing pain in a subject with nicotinic agonists, salts, hydrates, solvates, prodrugs or metabolites thereof and opioid agonists, salts, hydrates, solvates, prodrugs or metabolites thereof.

2006012, Jun 15, 2006

Jul 13, 2005

11/181369

Steven Shafer - Mountain View CA, US
Pamela Flood - Closter NJ, US
Thomas Jenkins - La Honda CA, US

A61K 31/4439
A61K 31/60
A61K 31/415
A61K 31/405
A61K 31/192

514159000, 514338000, 514343000, 514165000, 514406000, 514569000, 514570000, 514420000

Disclosed herein are compositions of nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents salts, hydrates, solvates or prodrugs thereof, pharmaceutical compositions thereof and methods of using these compositions and pharmaceutical compositions thereof to treat or prevent disease or pain in a subject. Also disclosed are methods of treating disease or pain or preventing disease or pain in a subject with nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents, salts, hydrates, solvates or prodrugs thereof.

2006016, Jul 27, 2006

Jan 27, 2005

11/044445

Michel MRF Struys - Belsele, BE
Tom Smet - Temse, BE
Steven Shafer - Mountain View CA, US

Aspect Medical Systems, Inc. - Newton MA

A61B 5/00
A61K 9/22

705003000, 604890100

The present invention provides a system and method for determining and maintaining a concentration level of medication in a patient sufficient to achieve and maintain a desired effect on that patient. Generally speaking, in accordance with one embodiment of the invention, a medication delivery controller uses a patient response profile to determine a concentration of medication in the patient that will achieve the desired effect on the patient. The patient response profile is a graphical, tabular or analytical expression of the relationship between the concentration of a medication and the effect of the medication at the specific concentration. Using this information, the medication delivery controller provides instructions to a medication delivery unit such as, for example, an infusion pump or inhalation device, to deliver the medication to the patient at a rate that will achieve the desired concentration level of the medication in the patient.

2010018, Jul 29, 2010

Jan 15, 2010

12/688762

Steven Louis SHAFER - Mountain View CA, US
Orlando Ricardo HUNG - Halifax, CA
Diana Helen PLIURA - Mississauga, CA

YM BIOSCIENCES INC. - Mississauga

A61K 9/127
A61K 31/445
A61K 31/485
A61P 25/04
A61M 15/00

424450, 514329, 514282, 12820315

An opioid formulation for pulmonary administration in the treatment or management of pain, a pulmonary drug delivery device containing, method of administering, kit containing, and uses of same. The formulation contains at least one rapid-onset opioid and preferably also contains a sustained-effect opioid to reduce the frequency of administration. The invention employs the side effects of the opioid formulation to permit patients to self-limit drug intake, thereby avoiding toxicity while achieving analgesia. A pharmacokinetic and pharmacodynamic model is employed to determine optimum drug formulations and optimum parameters for administration.